Cita APA

Fala, L. (2015). Trulicity (Dulaglutide): A New GLP-1 Receptor Agonist Once-Weekly Subcutaneous Injection Approved for the Treatment of Patients with Type 2 Diabetes. Am Health Drug Benefits.

Chicago Style Citation

Fala, Loretta. "Trulicity (Dulaglutide): A New GLP-1 Receptor Agonist Once-Weekly Subcutaneous Injection Approved for the Treatment of Patients With Type 2 Diabetes." Am Health Drug Benefits 2015.

Cita MLA

Fala, Loretta. "Trulicity (Dulaglutide): A New GLP-1 Receptor Agonist Once-Weekly Subcutaneous Injection Approved for the Treatment of Patients With Type 2 Diabetes." Am Health Drug Benefits 2015.